ferumoxytol

This page shows the latest ferumoxytol news and features for those working in and with pharma, biotech and healthcare.

Amag buys into maternal health business

Adding Makena into its portfolio will give Amag an opportunity in future to increase sales of its own flagship product Feraheme (ferumoxytol), used to treat iron-deficiency anaemia in patients with

Latest news

Death leads to recall of batch of Takeda's Rienso in Switzerland

Marketing partner Amag also reports three other hypersensitivity reactions. Takeda has recalled a batch of its anaemia medicine Rienso (ferumoxytol) in Switzerland following four reports of hypersensitivity reactions, including one death.
SMC approves Eliquis, restricts use of Rienso

Meanwhile the SMC's latest round of decisions also saw it back the restricted use of Takeda's treatment for iron deficiency anaemia in chronic kidney disease (CKD) Rienso (ferumoxytol).
Orphan drug focus

318. AMAG Pharmaceuticals/ Takeda. feraheme (ferumoxytol) - for iron deficiency anaemia.
Takeda to cut 10 per cent of jobs

and Feraheme (ferumoxytol) for anaemia associated with chronic renal failure.

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

Interview: Trevor Smith, Takeda

iron deficiency anaemia treatment Rienso (ferumoxytol) in June.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Spectrum appoints chief medical officer

2013. The appointment is a return to oncology for Dr Allen following a six-year spell as chief medical officer at AMAG Pharmaceuticals – the developer of Feraheme (ferumoxytol) for the treatment

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Medical (Scientific) Director: £120, 000 benefits

Senior Account Executive with progression to Account Manager, Me...: Excellent package

Systematic Reviewer - Oxford: Negotiable

Editorial Manager - MedComms: DOE

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Senior Account Manager: Competitive Salary Offered

Account Manager: Negotiable

Account Executive/ Senior Account Executive: competitive Salary Offfered

Associate Medical Director: Excellent PTO, bonus and 401k package

Account Manager- Healthcare Advertising: Negotiable

Associate Director: £75, 000-90, 000

Digital Communications Lead, Healthcare Brand and Medical Commun...: up to £50K

Experienced Medical Writers: Competitive Salary and Benefits

Account Director – Healthcare Marketing – Berks: Salary TBC

Medical Writer: Bonus Scheme, PTO &Private Healthcare

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Healthcare Communications Account Directors x 2: Salary TBC

Senior Editorial Assistant – Greater Manchester: DOE

Senior Developer with management potential, Healthcare Brand Com...: circa £50K

Account Director: Competitive Salary Offered

Principal Health Economist - North-West: Negotiable

Account Manager / Senior Account Manager: 35, 000-40, 000

Manager - Immunology, Therapeutic Area Communications & Publ...: Competitive Salary Offered

Medical Writer: Salary TBC

Account Manager / Account Director: Competative

Subscribe to our email news alerts

PMHub

Add my company

M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

AstraZeneca’s oncology renaissance: Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis: Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls: ‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...